

Deepak Nitrite Ltd. (DNL)

| | |
|---------------------------------|-----------------|
| No. of shares (m) | 136.4 |
| Mkt cap (Rs crs/\$m) | 29600/3576.2 |
| Current price (Rs/\$) | 2170/26.2 |
| Price target (Rs/\$) | 2426/29.3 |
| 52 W H/L (Rs.) | 2356/1730 |
| Book Value (Rs/\$) | 303/3.7 |
| Beta | 0.9 |
| Daily volume NSE (avg. monthly) | 514820 |
| P/BV (FY24e/25e) | 6.3/5.2 |
| EV/EBITDA (FY24e/25e) | 22.8/17.4 |
| P/E (FY24e/25e) | 36.3/26.8 |
| EPS growth (FY23/24e/25e) | -20.0/-4.4/35.2 |
| OPM (FY23/24e/25e) | 16.2/16.0/18.3 |
| ROE (FY23/24e/25e) | 23.6/18.8/21.2 |
| ROCE(FY23/24e/25e) | 22.9/18.6/21.1 |
| D/E ratio (FY23/24e/25e) | 0.0/0.0/0.0 |
| BSE Code | 506401 |
| NSE Code | DEEPAKNT |
| Bloomberg | DN IN |
| Reuters | DPNT.NS |

Shareholding pattern

| | % |
|-----------------------------|--------------|
| Promoters | 49.1 |
| MFs / Banks / FIs | 15.6 |
| Foreign Portfolio Investors | 8.1 |
| Govt. Holding | - |
| Public & others | 27.2 |
| Total | 100.0 |

As on June 30, 2023

Recommendation

ACCUMULATE

Analyst

KISHAN GUPTA, CFA, FRM

Phone: + 91 (33) 4488 0043

E- mail: kishan.gupta@cdequi.com

Company brief

Sorted into advanced intermediates and phenolics, DNL's product portfolio comprises organic, inorganic and fine chemicals.

Highlights

- DNL was no exception to other chemical manufacturers for it reported over 14% drop in revenues last quarter all thanks to global destocking of inventory and slowdown in Euro zone which resulted in both lower product realizations and subdued volume growth. Despite operating at a record utilization (~135%), DNL's phenol business witnessed some 20% drop in revenues. Its advanced intermediates business was a victim of high inflation and slowdown in Euro zone. Yet some green shoots are visible in some ser industries like construction and automobile which could galvanize volumes in quarters to come.
- Dumping by China, post reopening, has no puny ramifications for it led to pricing pressures in both phenol and AI businesses, which led to lower margins. Wherefore, phenol spread contracted, aptly demonstrated in perceptible drop in EBIT margins - 8.2% Vs 14.1% in Q1of previous fiscal Vs 15.1% in Q4FY23. Margins in AI business also saw a drop of some 200 bps last quarter. Lower OPMs spell doom for operating profits drop by a nerve -wracking 41.1% and post tax earnings collapsed by 36.1% to Rs 149.90 as compared to Rs 234.62 crs in the same period a year ago.
- Despite stress in phenol margins and plant maintenance shutdown for some 15days, DNL managed to all but retain its market share. Its production volumes is expect to rise not least due to enhanced capacity post debottlenecking and roll out of downstream products some time next fiscal. Yet uncertainty in global phenol markets - with increased participation of China – can have adverse consequences.
- The stock currently trades at 36.3x FY24e EPS of Rs 59.84 and 26.8x FY25e EPS of Rs 80.88. Earnings growth of over 35% next fiscal rest on the premise that margins in both phenol and AI businesses will improve. Yet risk that Euro zone slowdown will become more entrenched or that China will play a hard hand in global chemical markets cannot be dismissed by any stretch of imagination. Still DNL's ability to run capacities at higher utilization has no small cost advantages for it would prevent dismal erosion in earnings. Balancing odds, we assign accumulate rating on the stock with revised target of Rs 2426 (previous target: Rs 2504) based on 30x FY25e earnings.

| Consolidated (Rs crs) | FY21 | FY22 | FY23 | FY24e | FY25e |
|---|---------|---------|---------|---------|---------|
| Income from operations | 4359.75 | 6802.19 | 7972.06 | 7771.15 | 8905.47 |
| Other Income | 21.52 | 42.61 | 47.58 | 40.87 | 53.51 |
| EBITDA (other income included) | 1271.68 | 1648.52 | 1338.86 | 1282.41 | 1684.62 |
| Profit after associate profit (adjusted for EO) | 777.20 | 1067.21 | 853.71 | 816.16 | 1103.13 |
| EPS (Rs) | 56.98 | 78.24 | 62.59 | 59.84 | 80.88 |
| EPS growth (%) | 26.2 | 37.3 | -20.0 | -4.4 | 35.2 |

Outlook & Recommendation

Global Phenol Update

According to a report by ChemAnalyst, the global phenol market which stood at some 10.8 mn tons in 2022 is estimated to grow by 3.6% during the forecast period until 2035. The primary growth driver for the industry includes synthesis of chemicals and their derivatives. Of take of bisphenol A, which comprise 40% of the global phenol market in 2022, is expected to dominate the market in coming years as well.

Modor Intelligence reckons that increasing demand for polycarbonate and epoxy resins in various user industries such as paints and coatings, adhesives, electrical and electronics, packaging and other user industries is one of the factors responsible for the growth of Bisphenol-A (BPA) market. Polycarbonate plastic, which is synthesized using bisphenol A as raw material, would also see higher demand in the forecast period not least due to its wider application in various consumer products.



Source: Persistence Market Research

Source: Modor Intelligence

Asia Pacific would lead the volumes of phenol as it has in the past - accounted for more than 50% of the global market in 2022. With Asia Pacific region constituting a number of growing economies, the demand for plastics in various sectors like packaging, food, beverage and transportation would accelerate demand for phenol in the forecast period. After Asia Pacific, Europe and North America would occupy significant market positions.



Source: Modor Intelligence


According to Persistence Market Research, increasing use of phenol as an industrial cleaner for electronic devices and machinery parts would drive market growth. Growth would also be fueled by rising use of phenol in everyday products such as mouthwash, disinfectants, inks, liquid detergents and floor cleaners. In India, the increasing adoption of phenols in pharmaceutical industry for manufacture has no small growth potential.

Financials & Valuation

Prospects of Indian chemical industry, specialty chemicals in particular, barely appear to diminish not least due to growing need among global companies to build alternate sourcing channels, GOI's increased emphasis on self reliance and stricter regulatory compliance in China. Import substitution have become a preferred business growth strategy for leading Indian chemical firms and Deepak Nitrite is no exception - it has managed to build cost efficient capacities of phenol and acetone which have remarkably substituted imports. Yet, China's envious clout and volatility in crude oil prices have proved perilous to chemical manufacturers of other nations.


To stimulate business scaling and gain competitive advantage through enhanced cost efficiencies, DNL has mapped out barely unambitious capex plans over the next few years. One project which hogged the limelight was a Rs 5000 crs project Deepak Chem Tech Ltd, a wholly owned subsidiary of Deepak Nitrite, signed with Government of Gujarat for setting up manufacturing facilities of specialty chemicals, phenol/acetone and bisphenol. Aimed at import substitution, this four year project largely targets enhanced capacities of firm's existing products.

Other seemingly less famed expansion projects include downstream derivatives of phenol and acetone (read: MIBK and MIBC plants), debottlenecking phenol plant, new chemistries like photo chlorination and fluorination, and acid plant. The debottlenecking of phenol, which would get over soon, ensure capacity expansion by some 10%, while the acid plant would commence by the end of current fiscal. The MIBK and MIBC projects would see the light of day by middle of next fiscal.



Yet impediments to business scaling from China's intervention in phenol markets and wobbly trends in exports may have distinguishing impact. In light of slowdown in global chemical industry, DNL's record capex program appears misaligned with medium term prospects, thus invoking risks of underutilization of capacities and cost overruns. Capacities of newer products doubtlessly face higher gestation periods before achieving stabilization of an acceptable sort.

The stock currently trades at 36.3x FY24e EPS of Rs 59.84 and 26.8x FY25e EPS of Rs 80.88. Moderation in finished product prices in general has made the recovery arduous and prolonged, thus invoking need for increased specialization - somewhat visible in DNL's phenol business. Boosted by gradual recovery in margins, earnings are estimated to rise by over 35% next fiscal; higher utilization of phenol facility coupled with downstream derivatives of phenol and acetone could act as catalysts. Weighed down by margins, earning for the current fiscal is estimated to reduce by a third. Balancing odds, we assign accumulate rating on the stock with revised target of Rs 2426 (previous target: Rs 2504) based on 30x FY25e earnings. For more info refer to our December report.



Cross Sectional Analysis




| Company | Equity (Rs crs) | CMP (Rs crs) | Mcap (Rs crs) | Inc. from ops. (Rs crs) | Profit (Rs crs) | OPM (%) | NPM (%) | Int. cov. | ROE (%) | Mcap / IO | P/BV | P/E |
|----------------|-----------------|--------------|---------------|-------------------------|-----------------|---------|---------|-----------|---------|-----------|------|------|
| Atul Ltd | 30 | 7199 | 21247 | 5133 | 430 | 14.1 | 8.1 | 69.1 | 9.4 | 4.1 | 4.5 | 49.4 |
| Deepak Nitrite | 27 | 2170 | 29600 | 7682 | 769 | 14.9 | 10.0 | 52.9 | 20.2 | 3.9 | 7.2 | 38.5 |
| Sudarshan | 14 | 515 | 3565 | 2356 | 59 | 10.3 | 2.5 | 2.6 | 7.2 | 1.5 | 3.3 | 60.7 |

calculations on ttm basis

Companies not truly comparable due to product dissimilarities

Distinct slowdown in Atul's both domestic and overseas markets have scarcely deterred its expansion plans with projects totaling Rs 1420 crs are at different stages of implementation at its standalone entity (Rs 561 crs) and various entities including Atul Products (Rs 817 crs) and Atul Finserv. Capacity of caustic soda is expected to come on stream sometime in the current quarter, while the reconstruction of pharmaceutical plant, which was affected by fire, is expected to get over by Q2 of current fiscal. Competitive advantage in terms of good market share in some key products coupled with benefits of integration and overseas market presence has envious business scaling power. It has managed to contain capital costs thanks to product specialization and debottlenecking.

For boosting its overseas presence, Sudarshan Chemicals has begun seeking growth opportunities through increased competitiveness in overseas markets. Plans are afoot to increase penetration in select international geographies while expand its product portfolio to build a comprehensive product range. To optimize costs, integration costs would be taken up which would also help in achieving increased efficiency of value chain. Business scaling would cling to higher capex and gradual improvement in demand of global pigments industry.



Financials

Income Statement - Consolidated

Figures in Rs crs

| | Q1FY24 | Q1FY23 | % chg. | FY23 | FY22 | % chg. |
|--------------------------------------|----------------|----------------|--------------|----------------|----------------|--------------|
| Income from operations | 1961.65 | 1681.35 | 16.7 | 4019.64 | 3207.57 | 25.3 |
| Other Income | 12.04 | 8.43 | 42.8 | 21.65 | 16.68 | 29.8 |
| Total Income | 1973.69 | 1689.78 | 16.8 | 4041.29 | 3224.25 | 25.3 |
| Total Expenditure | 1690.80 | 1294.81 | 30.6 | 3392.81 | 2369.53 | 43.2 |
| PBIDT (other income included) | 282.89 | 394.97 | -28.4 | 648.48 | 854.72 | -24.1 |
| Interest | 5.90 | 9.24 | -36.1 | 14.49 | 20.18 | -28.2 |
| Depreciation | 42.40 | 44.05 | -3.7 | 84.28 | 87.61 | -3.8 |
| PBT | 234.59 | 341.68 | -31.3 | 549.71 | 746.93 | -26.4 |
| Tax | 60.12 | 87.34 | -31.2 | 140.62 | 189.96 | -26.0 |
| PAT | 174.47 | 254.34 | -31.4 | 409.09 | 556.97 | -26.6 |
| MI | - | - | - | - | - | - |
| Net profit after MI | 174.47 | 254.34 | -31.4 | 409.09 | 556.97 | -26.6 |
| Extraordinary Item | - | - | - | - | - | - |
| Adjusted Net Profit | 174.47 | 254.34 | -31.4 | 409.09 | 556.97 | -26.6 |
| EPS (F.V. 2) | 12.79 | 18.65 | -31.4 | 29.99 | 40.83 | -26.6 |

Segment Results

Figures in Rs crs

| | Q1FY24 | Q1FY23 | % chg. | FY23 | FY22 | % chg. |
|--|----------------|----------------|--------------|----------------|----------------|--------------|
| Segment Revenue | | | | | | |
| Advanced Intermediates | 685.30 | 544.40 | 25.9 | 1415.28 | 1071.65 | 32.1 |
| Phenolics | 1284.08 | 1139.22 | 12.7 | 2619.01 | 2138.30 | 22.5 |
| Total | 1969.38 | 1683.62 | 17.0 | 4034.29 | 3209.95 | 25.7 |
| Inter segment revenue | 7.73 | 2.27 | 240.5 | 14.65 | 2.38 | 515.5 |
| Income from operations* | 1961.65 | 1681.35 | 16.7 | 4019.64 | 3207.57 | 25.3 |
| Segment EBIT | | | | | | |
| Advanced Intermediates | 138.35 | 128.38 | 7.8 | 271.05 | 255.92 | 5.9 |
| Phenolics | 102.66 | 220.39 | -53.4 | 290.40 | 507.65 | -42.8 |
| Total | 241.01 | 348.77 | -30.9 | 561.45 | 763.57 | -26.5 |
| Interest | 5.90 | 9.24 | -36.1 | 14.49 | 20.18 | -28.2 |
| Other Unallocable Exp. (net of income) | 0.51 | -2.15 | -123.7 | -2.76 | -3.54 | -22.0 |
| PBT | 234.59 | 341.68 | -31.3 | 549.71 | 746.93 | -26.4 |

Financials

Income Statement - Consolidated

Figures in Rs crs

| | FY21 | FY22 | FY23 | FY24e | FY25e |
|---------------------------------------|----------------|----------------|----------------|----------------|----------------|
| Income from operations | 4359.75 | 6802.19 | 7972.06 | 7771.15 | 8905.47 |
| <i>Growth (%)</i> | 3.1 | 56.0 | 17.2 | -2.5 | 14.6 |
| Other Income | 21.52 | 42.61 | 47.58 | 40.87 | 53.51 |
| Total Income | 4381.27 | 6844.80 | 8019.64 | 7812.02 | 8958.98 |
| Total Expenditure | 3109.59 | 5196.28 | 6680.78 | 6529.62 | 7274.36 |
| EBITDA (other income included) | 1271.68 | 1648.52 | 1338.86 | 1282.41 | 1684.62 |
| Interest | 77.33 | 36.37 | 26.68 | 8.22 | 7.93 |
| EBDT | 1194.35 | 1612.15 | 1312.18 | 1274.19 | 1676.68 |
| Depreciation | 152.63 | 177.70 | 166.30 | 177.20 | 193.98 |
| Tax | 265.91 | 367.81 | 293.88 | 280.83 | 379.57 |
| Net profit after MI | 775.81 | 1066.64 | 852.00 | 816.16 | 1103.13 |
| Extraordinary item | -1.39 | -0.57 | -1.71 | - | - |
| Adjusted Net Profit | 777.20 | 1067.21 | 853.71 | 816.16 | 1103.13 |
| EPS (Rs.) | 56.98 | 78.24 | 62.59 | 59.84 | 80.88 |

Segment Results

Figures in Rs crs

| | FY22 | FY23 | FY24e | FY25e |
|--|----------------|----------------|----------------|----------------|
| Segment Revenue | | | | |
| Advanced Intermediates | 2511.05 | 3033.55 | 3242.24 | 3728.57 |
| Phenolics | 4303.42 | 4970.49 | 4561.34 | 5214.18 |
| Total | 6814.47 | 8004.04 | 7803.57 | 8942.75 |
| Inter segment revenue | 12.28 | 31.98 | 32.42 | 37.29 |
| Income from operations | 6802.19 | 7972.06 | 7771.15 | 8905.47 |
| Segment EBIT | | | | |
| Advanced Intermediates | 595.73 | 555.06 | 596.36 | 708.43 |
| Phenolics | 867.11 | 594.46 | 506.83 | 782.13 |
| Sub Total | 1462.84 | 1149.52 | 1103.19 | 1490.56 |
| Interest | 34.05 | 24.77 | 8.22 | 7.93 |
| Other Unallocable Exp. (net of income) | -5.66 | -21.13 | -2.02 | -0.08 |
| PBT | 1434.45 | 1145.88 | 1096.98 | 1482.70 |

Consolidated Balance Sheet

Figures in Rs crs

| | FY21 | FY22 | FY23 | FY24e | FY25e |
|---|----------------|----------------|----------------|----------------|----------------|
| SOURCES OF FUNDS | | | | | |
| Share Capital | 27.28 | 27.28 | 27.28 | 27.28 | 27.28 |
| Reserves | 2319.37 | 3311.16 | 4062.68 | 4776.55 | 5777.38 |
| Total Shareholders Funds | 2346.65 | 3338.44 | 4089.95 | 4803.83 | 5804.66 |
| Long term debt | 534.80 | 200.37 | 58.43 | 53.43 | 48.43 |
| Total Liabilities | 2881.45 | 3538.81 | 4148.38 | 4857.26 | 5853.09 |
| APPLICATION OF FUNDS | | | | | |
| Gross Block | 2292.53 | 2566.85 | 2707.17 | 3057.17 | 3457.17 |
| Less: Accumulated Depreciation | 428.80 | 603.43 | 765.56 | 942.76 | 1136.74 |
| Net Block | 1863.73 | 1963.42 | 1941.61 | 2114.41 | 2320.43 |
| Capital Work in Progress | 220.44 | 122.23 | 300.83 | 350.00 | 400.00 |
| Investments | 189.29 | 439.02 | 379.35 | 552.48 | 1052.48 |
| Current Assets, Loans & Advances | | | | | |
| Inventory | 382.69 | 584.55 | 893.07 | 1071.68 | 1286.02 |
| Sundry Debtors | 756.30 | 1129.06 | 1309.52 | 1440.47 | 1584.52 |
| Cash and Bank | 33.43 | 41.79 | 39.95 | 66.89 | 13.91 |
| Other Assets | 92.97 | 92.55 | 119.66 | 95.45 | 109.65 |
| Total CA & LA | 1265.39 | 1847.95 | 2362.20 | 2674.50 | 2994.10 |
| Current liabilities | 543.10 | 739.22 | 779.39 | 740.86 | 834.89 |
| Provisions | 10.38 | 7.70 | 14.37 | 10.00 | 12.00 |
| Total Current Liabilities | 553.48 | 746.92 | 793.76 | 750.86 | 846.89 |
| Net Current Assets | 711.91 | 1101.03 | 1568.44 | 1923.64 | 2147.21 |
| Net Deferred Tax (net of liability) | -107.81 | -122.87 | -156.47 | -176.47 | -196.47 |
| Other Assets (Net of liabilities) | 3.88 | 35.98 | 114.63 | 93.20 | 129.44 |
| Total Assets | 2881.45 | 3538.81 | 4148.38 | 4857.26 | 5853.09 |

Key Financial Ratios

| | FY21 | FY22 | FY23 | FY24e | FY25e |
|-----------------------------|------|------|-------|-------|-------|
| Growth Ratios | | | | | |
| Revenue (%) | 3.1 | 56.0 | 17.2 | -2.5 | 14.6 |
| EBIDTA (%) | 19.0 | 29.5 | -18.8 | -4.3 | 31.4 |
| Net Profit (%) | 26.2 | 37.3 | -20.0 | -4.4 | 35.2 |
| EPS (%) | 26.2 | 37.3 | -20.0 | -4.4 | 35.2 |
| Margins | | | | | |
| Operating Profit Margin (%) | 28.7 | 23.6 | 16.2 | 16.0 | 18.3 |
| Gross Profit Margin (%) | 27.4 | 23.7 | 16.5 | 16.4 | 18.8 |
| Net Profit Margin (%) | 17.8 | 15.7 | 10.7 | 10.5 | 12.4 |
| Return | | | | | |
| ROCE (%) | 30.2 | 34.1 | 22.9 | 18.6 | 21.1 |
| ROE (%) | 40.4 | 38.7 | 23.6 | 18.8 | 21.2 |
| Valuations | | | | | |
| Market Cap / Sales | 5.2 | 4.5 | 3.2 | 3.8 | 3.3 |
| EV/EBIDTA | 18.0 | 18.5 | 18.5 | 22.8 | 17.4 |
| P/E | 29.1 | 28.7 | 29.4 | 36.3 | 26.8 |
| P/BV | 9.9 | 9.4 | 6.3 | 6.3 | 5.2 |
| Other Ratios | | | | | |
| Interest Coverage | 14.5 | 40.5 | 44.0 | 134.4 | 187.9 |
| Debt-Equity Ratio | 0.3 | 0.1 | 0.0 | 0.0 | 0.0 |
| Current Ratio | 2.3 | 2.7 | 3.1 | 3.8 | 4.2 |
| Turnover Ratios | | | | | |
| Fixed Asset Turnover | 2.4 | 3.6 | 4.1 | 3.8 | 4.0 |
| Total Asset Turnover | 1.7 | 2.2 | 2.1 | 1.8 | 1.7 |
| Debtors Turnover | 6.4 | 7.2 | 6.5 | 5.7 | 5.9 |
| Inventory Turnover | 8.0 | 10.7 | 9.0 | 6.6 | 6.2 |
| Creditors Turnover | 7.8 | 11.0 | 11.4 | 10.2 | 10.9 |
| WC Ratios | | | | | |
| Debtor Days | 57.3 | 50.6 | 55.8 | 64.6 | 62.0 |
| Inventory Days | 45.6 | 34.0 | 40.4 | 54.9 | 59.2 |
| Creditor Days | 47.0 | 33.3 | 32.1 | 35.9 | 33.5 |
| Cash Conversion Cycle | 55.9 | 51.2 | 64.1 | 83.6 | 87.7 |

Cumulative Financial Data

| Figures in Rs crs | FY20-22 | FY23-25e |
|---------------------------|---------|----------|
| Income from operations | 15392 | 24649 |
| Operating profit | 3894 | 4165 |
| EBIT | 3523 | 3770 |
| PBT | 3290 | 3727 |
| PAT | 2460 | 2773 |
| Dividends | 244 | 314 |
| OPM (%) | 25.3 | 16.9 |
| NPM (%) | 16.0 | 11.3 |
| Interest coverage | 15.2 | 88.0 |
| ROE (%) | 38.3 | 20.7 |
| ROCE (%) | 30.4 | 20.1 |
| Debt-equity ratio* | 0.1 | 0.0 |
| Fixed asset turnover | 2.8 | 3.8 |
| Debtors turnover | 6.0 | 6.1 |
| Inventory turnover | 7.7 | 7.3 |
| Creditors turnover | 7.8 | 11.2 |
| Debtors days | 60.6 | 60.3 |
| Inventory days | 47.4 | 50.0 |
| Creditor days | 46.9 | 32.7 |
| Cash conversion cycle | 61.1 | 77.6 |
| Dividend payout ratio (%) | 10.0 | 11.3 |

FY20-22 implies three years ending fiscal 22; *as on terminal year; consolidated data

Recognizable euphoria witnessed during Covid 19 pandemic seems to have waned as is visible in barely healthy trend in earnings in the last few quarters. Wherefore, cumulative earnings during FY23-25 period (though some recovery is expected next fiscal) is estimated to jump by a little enthralling 13% (see table) on the back of some 60% growth in cumulative revenues. Thanks to striking drop in global phenol and acetone prices, overall OPMs is projected to decline to 16.9% during FY23-25 period from 25.3%. Phenol margins (EBIT) after peaking during Covid 19 has stabilized at mid teens in the last few quarters.

Record capacity utilization in phenol plant would barely help matters for the ROE is estimated to decline to an abysmal 20.7% during FY23-25 period from some 38% in the preceding period. Stress in earnings largely explains much of the sclerosis in return on capital - ROCE also estimated to plunge to 20.1% from 30.4% in FY20-22 period. Cash conversion cycle is estimated to perceptibly increase from 61 days to ~78 days not least due to sharp decline in creditor days - partly as a result of improved liquidity with the firm (see table).

Financial Summary – US dollar denominated

| million \$ | FY21 | FY22 | FY23 | FY24e | FY25e |
|-------------------------------|-------|-------|-------|-------|--------|
| Equity capital | 3.7 | 3.6 | 3.3 | 3.3 | 3.3 |
| Shareholders funds | 309.0 | 427.8 | 485.0 | 568.0 | 688.1 |
| Total debt | 80.0 | 41.4 | 8.5 | 8.3 | 7.7 |
| Net fixed assets (incl CWIP) | 283.5 | 275.1 | 272.7 | 297.7 | 328.7 |
| Investments | 25.8 | 57.9 | 46.1 | 66.7 | 127.2 |
| Net current assets | 86.6 | 132.6 | 178.3 | 220.0 | 246.2 |
| Total assets | 381.8 | 454.2 | 492.1 | 574.5 | 694.0 |
| Revenues | 587.6 | 912.9 | 991.6 | 938.9 | 1075.9 |
| EBITDA | 171.6 | 221.3 | 166.7 | 154.9 | 203.5 |
| EBDT | 161.2 | 216.5 | 163.4 | 153.9 | 202.6 |
| PBT | 140.4 | 192.6 | 142.7 | 132.5 | 179.1 |
| Profit after associate profit | 104.7 | 143.2 | 106.2 | 98.6 | 133.3 |
| EPS(\$) | 0.77 | 1.05 | 0.78 | 0.72 | 0.98 |
| Book value (\$) | 2.27 | 3.14 | 3.56 | 4.16 | 5.05 |

income statement figures translated at average rates; balance sheet and cash flow at year end rates; projections at current rates (Rs 82.77/\$). All dollar denominated figures adjusted for extraordinary items.

Disclosure & Disclaimer

CD Equisearch Private Limited (hereinafter referred to as 'CD Equi') is a Member registered with National Stock Exchange of India Limited, Bombay Stock Exchange Limited and Metropolitan Stock Exchange of India Limited (Formerly known as MCX Stock Exchange Limited). CD Equi is also registered as Depository Participant with CDSL and AMFI registered Mutual Fund Advisor. The associates of CD Equi are engaged in activities relating to NBFC-ND - Financing and Investment, Commodity Broking, Real Estate, etc.

CD Equi is registered under SEBI (Research Analysts) Regulations, 2014 with SEBI Registration no INH300002274. Further, CD Equi hereby declares that –

- No disciplinary action has been taken against CD Equi by any of the regulatory authorities.
- CD Equi/its associates/research analysts do not have any financial interest/beneficial interest of more than one percent/material conflict of interest in the subject company(s) (*kindly disclose if otherwise*).
- CD Equi/its associates/research analysts have not received any compensation from the subject company(s) during the past twelve months.
- CD Equi/its research analysts has not served as an officer, director or employee of company covered by analysts and has not been engaged in market making activity of the company covered by analysts.

This document is solely for the personal information of the recipient and must not be singularly used as the basis of any investment decision. Nothing in this document should be construed as investment or financial advice. Each recipient of this document should make such investigations as they deem necessary to arrive at an independent evaluation of an investment in the securities of the companies referred to in this document (including the merits and risks involved) and should consult their own advisors to determine the merits and risks of such an investment.

Reports based on technical and derivative analysis center on studying charts of a stock's price movement, outstanding positions and trading volume, as opposed to focusing on a company's fundamentals and as such, may not match with a report on a company's fundamentals.

The information in this document has been printed on the basis of publicly available information, internal data and other reliable sources believed to be true but we do not represent that it is accurate or complete and it should not be relied on as such, as this document is for general guidance only. CD Equi or any of its affiliates/group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. CD Equi has not independently verified all the information contained within this document. Accordingly, we cannot testify nor make any representation or warranty, express or implied, to the accuracy, contents or data contained within this document.

While, CD Equi endeavors to update on a reasonable basis the information discussed in this material, there may be regulatory compliance or other reasons that prevent us from doing so.

This document is being supplied to you solely for your information and its contents, information or data may not be reproduced, redistributed or passed on, directly or indirectly. Neither, CD Equi nor its directors, employees or affiliates shall be liable for any loss or damage that may arise from or in connection with the use of this information.

CD Equisearch Private Limited (CIN: U67120WB1995PTC071521)

Registered Office: 37, Shakespeare Sarani, 3rd Floor, Kolkata – 700 017; Phone: +91(33) 4488 0000; Fax: +91(33) 2289 2557 Corporate Office: 10, Vasawani Mansion, 5th Floor, DinshawWachha Road, Churchgate, Mumbai – 400 020. Phone: +91(22) 2283 0652/0653; Fax: +91(22) 2283, 2276 Website: www.cdequi.com; Email: research@cdequi.com

buy: >20% accumulate: >10% to ≤20% hold: ≥-10% to ≤10% reduce: ≥-20% to <-10% sell: <-20%

Exchange Rates Used- Indicative

| Rs/\$ | FY19 | FY20 | FY21 | FY22 | FY23 |
|----------|-------|-------|-------|-------|-------|
| Average | 69.89 | 70.88 | 74.20 | 74.51 | 80.39 |
| Year end | 69.17 | 75.39 | 73.50 | 75.81 | 82.22 |

All \$ values mentioned in the write-up translated at the average rate of the respective quarter/ year as applicable. Projections converted at current exchange rate. Cumulative dollar figure is the sum of respective yearly dollar value.